Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

PolandBack to Poland

Clinical trials in Olsztyn – page 7

302 clinical trials in Olsztyn, Poland across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Olsztyn at a glance
302
clinical trials
  • Research sites4
Type of trial
Recruitment status
Quick filters

302 trials in Olsztyn

Open in trial search

Prophylaxis of nausea and vomiting

Recruiting

Study on IV NEPA (Fosnetupitant/Palonosetron) for Preventing Chemotherapy-Induced Nausea and Vomiting in Pediatric Cancer Patients

Registered drug
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Fosaprepitant
  • Sponsor:Helsinn Healthcare S.A.

Myelodysplastic syndrome

Recruiting

Study on the Effectiveness of Lisaftoclax and Azacitidine in Adults with Newly Diagnosed Higher Risk Myelodysplastic Syndrome

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Ascentage Pharma Group Inc.

Anaemia+1

Recruiting

Study of Elritercept for Treating Anemia in Adults with Low to Intermediate Risk Myelodysplastic Syndromes

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Elritercept
  • Sponsor:Takeda Development Center Americas Inc.

Hypertension

Recruiting

Study of Optimal Treatment for Uncontrolled Hypertension Using Triple Drug Combinations (Olmesartan/Amlodipine/Hydrochlorothiazide or Perindopril/Indapamide/Amlodipine) with Additional Diuretics

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Amlodipine
  • Sponsor:Agencja Badań Medycznych

Colorectal cancer

Recruiting

Study Comparing Amivantamab and Drug Combination for Patients with Recurrent or Metastatic Colorectal Cancer Without KRAS/NRAS and BRAF Mutations

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:Janssen Cilag International

Small cell lung cancer limited stage

Recruiting

Study on Toripalimab and Tifcemalimab for Patients with Limited-Stage Small Cell Lung Cancer After Chemoradiotherapy

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Tifcemalimab
  • Sponsor:Shanghai Junshi Biosciences Co. Ltd.

Diffuse large B-cell lymphoma

Recruiting

Study of Zilovertamab Vedotin and Drug Combination for Untreated Diffuse Large B-Cell Lymphoma Patients

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Merck Sharp & Dohme LLC

Dry age-related macular degeneration+1

Recruiting

Study of Pozelimab and Cemdisiran for Adults with Geographic Atrophy from Age-Related Macular Degeneration

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Cemdisiran
  • Sponsor:Regeneron Pharmaceuticals Inc.

Colorectal cancer

Recruiting

Study Comparing Amivantamab and Chemotherapy Versus Cetuximab and Chemotherapy for Patients with Advanced Colorectal Cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:Janssen Cilag International

Hodgkin's disease

Recruiting

Study of Nivolumab for Early Stage Hodgkin Lymphoma in Patients with Good Prognosis

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Medical University Of Gdansk

Procedural hypotension

Recruiting

Study on the Effect of Norepinephrine Infusion for Managing Low Blood Pressure in Patients Undergoing Non-Cardiac Surgery

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Norepinephrine
  • Sponsor:Uniwersytet Jagiellonski Collegium Medicum

Plasma cell myeloma

Recruiting

Study on the Safety and Efficacy of Cevostamab with Lenalidomide or Iberdomide for Patients with High-Risk or Relapsed Multiple Myeloma

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Cevostamab
  • Sponsor:F. Hoffmann-La Roche AG

Other cities in Poland

The busiest research cities in the country

All 239 cities in Poland

Clinical research in Olsztyn

What the registry says about research in the country

01 Oncology Research

Clinical trials focusing on acute myeloid leukemia treatments and innovative therapies for various types of lung cancer. Studies include evaluation of new drug combinations and treatment approaches for colorectal cancer and lymphoma.

  • Advanced treatment combinations for leukemia
  • Targeted therapies for NSCLC
  • Novel approaches in lymphoma treatment

Research emphasizes personalized medicine approaches and improving patient outcomes in advanced stages of disease.

02 Dermatology Studies

Innovative research into plaque psoriasis and psoriatic arthritis treatments, including new biological therapies and novel drug combinations. Studies also examine treatments for rare conditions like pyoderma gangrenosum.

  • Biological therapy assessment
  • Chronic skin condition management
  • Combined treatment approaches

Focus on developing more effective treatments for moderate to severe skin conditions.

03 Cardiovascular Research

Studies examining new approaches to heart failure prevention and treatment, including investigations of novel drug combinations. Research focuses on reducing cardiovascular events and improving outcomes in high-risk patients.

  • Heart failure prevention strategies
  • Cardiovascular risk reduction
  • Therapeutic combinations

Emphasis on preventive measures and innovative treatment strategies for cardiac conditions.

Back to PolandAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.